Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Capmatinib - Novartis Oncology

Drug Profile

Capmatinib - Novartis Oncology

Alternative Names: INC-280; INCB-028060; INCB-28060; TABRECTA; Tabrecta

Latest Information Update: 19 Mar 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Incyte Corporation
  • Developer Array BioPharma; Novartis Oncology
  • Class Antineoplastics; Benzamides; Fluorobenzenes; Heterocyclic bicyclo compounds; Imidazoles; Quinolines; Small molecules; Triazines
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase II Glioblastoma; Liver cancer; Malignant melanoma; Renal cell carcinoma; Solid tumours
  • Phase I/II Colorectal cancer; Head and neck cancer
  • Phase I Breast cancer

Most Recent Events

  • 25 Mar 2021 Novartis plans the phase III GEOMETRY-E trial for Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in July 2021 (PO, Tablet) (NCT04816214 )
  • 16 Mar 2021 Celcuity, MD Anderson Cancer Center, Novartis Oncology and Puma Biotechnology enters a clinical trial collaboration for a phase II trial for Breast cancer (PO)
  • 16 Mar 2021 Celcuity, MD Anderson Cancer Center, Novartis Oncology and Puma Biotechnology plans a phase II trial for Breast cancer (Second-line therapy, Metastatic disease) in the second quarter of 2021 (PO,Tablet)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top